Streetbeat News

OTSKF

Otsuka Holdings Co.,Ltd.

Industry

Medicinal and Botanical Manufacturing

Open

51.22

Mkt cap

25B

Volume

High

51.22

P/E Ratio

10.96

52-wk high

66.15

Low

46.93

Div yield

0.02

52-wk low

38.36

IGC Pharma Inc (NYSE:IGC) announced positive interim Phase 2 trial results for IGC-AD1, showing significant reduction in Alzheimer's Disease agitation compared to placebo. The trial used the Cohen Mansfield Agitation Inventory for assessment, with notable improvements as early as week two. In contrast, Otsuka Holding Co Ltd's (OTC:OTSKY) (OTC:OTSKF) Rexulti received FDA approval with less pronounced effects in a similar context. IGC's stock dropped 13.80% to $0.33 following the announcement.

Portfolio Pulse from Vandana Singh

March 20, 2024 | 5:21 pm

Several mergers and acquisitions have been announced in the psychedelics sector. Cybin (NYSE:CYBN) is acquiring Small Pharma (OTC:DMTTF), Silo Wellness (OTC:SILFF) is buying NUGL Inc./Kaya Group (OTC:NUGL), and Mindset Pharma (OTC:MSSTF) is being acquired by Otsuka America Inc., part of Otsuka Holdings (OTC:OTSKF). Additionally, Psyched Wellness (OTC:PSYCF) is set to receive $7.5M in financing. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has seen a slight increase in its share price.

Portfolio Pulse from Lara Goldstein

September 05, 2023 | 2:08 pm

Mindset Pharma (OTC:MSSTF) has agreed to acquire all outstanding shares of Otsuka America Inc., the U.S. arm of Otsuka Pharmaceutical Co., for approximately $60 million. The transaction is expected to close on or around October 19, 2023. This acquisition follows Mindset's partnership with Otsuka’s McQuade Center for Strategic Research and Development (MSRD) in January 2022. The deal is seen as a way to maximize Mindset’s IP portfolio and assets value.

Portfolio Pulse from Lara Goldstein

August 31, 2023 | 5:54 pm

Medtronic's Symplicity Spyral RDN System, a device for treating high blood pressure, has faced a regulatory setback as the FDA Circulatory System Devices Panel voted against its approval, citing that the risks do not outweigh the benefits. Meanwhile, the same panel backed a similar device by Recor Medical and its parent company, Otsuka Medical Devices. Medtronic's shares fell 1.24% in premarket trading following the news.

Portfolio Pulse from Vandana Singh

August 24, 2023 | 12:45 pm

The FDA's Circulatory Systems Devices Panel has backed Recor Medical Inc and its parent company, Otsuka Medical Devices Co Ltd's (OTC:OTSKF) (OTC:OTSKY) hypertension treatment device, the Paradise Ultrasound RDN system. The panel voted unanimously in favor of the device's safety and majority in favor of its efficacy. If approved by the FDA, the device would be the first FDA-approved renal denervation device in the U.S. intended to reduce blood pressure in patients with uncontrolled hypertension.

Portfolio Pulse from Vandana Singh

August 23, 2023 | 1:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.